Renal cell carcinoma (RCC) comprises a heterogeneous group of histologically and
molecularly distinct tumour subtypes. Current targeted therapies have improved survival in …

Background Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal cell carcinoma
(ccRCC) that reflects the trajectory of evolution and influences clinical prognosis. Here we …

The tumor immune microenvironment plays a critical role in cancer progression and
response to immunotherapy in clear cell renal cell carcinoma (ccRCC), yet the composition …

Purpose Recurrent renal cell carcinoma (reRCC) is associated with poor prognosis and the
underlying mechanism is not yet clear. A comprehensive understanding of tumor …

Simple Summary Immune checkpoint inhibitor (ICI) therapy has proven effective for many
cancer patients, but predicting which patients with renal cell carcinoma (RCC) will respond …

Renal cell carcinoma (RCC) encompasses a wide spectrum of morphologically and
molecularly distinct (> 10) cancer subtypes originated from the kidney epithelium. Metastatic …

The selection of effective therapeutic agents is critical for improving the survival of patients
with renal cell carcinoma (RCC). The aim of the present study was to develop an ex vivo …

Simple Summary Clear cell renal cell carcinomas (ccRCC) have several distinct
immunological features, including a high degree of immune infiltration and relatively low …

Immune checkpoint blockade (ICB) therapies have improved the overall survival (OS) of
many patients with advanced cancers. However, the response rate to ICB varies widely …

Immune checkpoint inhibitors (ICI) have dramatically changed the treatment of metastatic
renal cell carcinoma (mRCC). Although many studies have reported biomarkers as …